United States: FDA's Office Of Prescription Drug Promotion Issues Its First Untitled Letter Of The Year To Novartis For Misleading Statement Relating To KISQALI® - Sheppard Mullin Richter & Hampton

On January 18, 2024, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued its first untitled letter of the new year to Novartis Pharmaceuticals Corporation...